Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Collen

Showing results (471-480 of 715) with videos related to

Pageof 72
Sort By:
Journal of Thrombosis and Haemostasis : JTH|June 11, 2005
On the role of plasminogen activator inhibitor-1 in adipose tissue development and insulin resistance in miceH R Lijnen, M-C Alessi, B Van Hoef, et al.
Thrombosis and Haemostasis|September 7, 1992
Synergistic antithrombotic properties of G4120, a RGD-containing synthetic peptide, and argatroban, a synthetic thrombin inhibitor, in a hamster femoral vein platelet-rich thrombosis modelY Imura, J M Stassen, I Vreys, et al.
Journal of Cardiovascular Pharmacology|December 16, 2000
tPA, but not uPA, significantly affects antithrombotic therapy by a glycoprotein IIb/IIIa antagonist, but not by a factor Xa inhibitorM Nishida, H Matsuno, O Kozawa, et al.
The Journal of Biological Chemistry|July 25, 1990
Biochemical and functional characterization of human tissue-type plasminogen activator variants with mutagenized kringle domainsD Collen, H R Lijnen, F Bulens, et al.
Thrombosis and Haemostasis|December 2, 1991
Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activatorT Kurokawa, S Iwasa, A Kakinuma, et al.
Thrombosis and Haemostasis|February 28, 1984
Effect of 24 hours of normoglycaemia on tissue-type plasminogen activator plasma levels in insulin-dependent diabetesI Juhan-Vague, P Vague, C Poisson, et al.
Circulation Research|November 1, 1990
Studies of recombinant plasminogen activator inhibitor-1 in rabbits. Pharmacokinetics and evidence for reactivation of latent plasminogen activator inhibitor-1 in vivoD E Vaughan, P J Declerck, E Van Houtte, et al.
Blood|October 15, 1990
Comparison of intravenous bolus injection or continuous infusion of recombinant single chain urokinase-type plasminogen activator (saruplase) for thrombolysis. A canine model of combined coronary arterial and femoral venous thrombosisH J Rapold, Z M Wu, T Stassen, et al.
The Journal of Clinical Investigation|January 1, 1994
Stimulation with a monoclonal antibody (mAb4E4) of scavenger receptor-mediated uptake of chemically modified low density lipoproteins by THP-1-derived macrophages enhances foam cell generationP Holvoet, G Perez, H Bernar, et al.
Thrombosis and Haemostasis|March 1, 1996
Characterization of a cDNA encoding murine coagulation factor VIIE Idusogie, E Rosen, J P Geng, et al.
Pageof 72

Showing results (471-480 of 715) with videos related to

Sort By:
Pageof 72
Journal of Thrombosis and Haemostasis : JTH|June 11, 2005
On the role of plasminogen activator inhibitor-1 in adipose tissue development and insulin resistance in miceH R Lijnen, M-C Alessi, B Van Hoef, et al.
Thrombosis and Haemostasis|September 7, 1992
Synergistic antithrombotic properties of G4120, a RGD-containing synthetic peptide, and argatroban, a synthetic thrombin inhibitor, in a hamster femoral vein platelet-rich thrombosis modelY Imura, J M Stassen, I Vreys, et al.
Journal of Cardiovascular Pharmacology|December 16, 2000
tPA, but not uPA, significantly affects antithrombotic therapy by a glycoprotein IIb/IIIa antagonist, but not by a factor Xa inhibitorM Nishida, H Matsuno, O Kozawa, et al.
The Journal of Biological Chemistry|July 25, 1990
Biochemical and functional characterization of human tissue-type plasminogen activator variants with mutagenized kringle domainsD Collen, H R Lijnen, F Bulens, et al.
Thrombosis and Haemostasis|December 2, 1991
Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activatorT Kurokawa, S Iwasa, A Kakinuma, et al.
Thrombosis and Haemostasis|February 28, 1984
Effect of 24 hours of normoglycaemia on tissue-type plasminogen activator plasma levels in insulin-dependent diabetesI Juhan-Vague, P Vague, C Poisson, et al.
Circulation Research|November 1, 1990
Studies of recombinant plasminogen activator inhibitor-1 in rabbits. Pharmacokinetics and evidence for reactivation of latent plasminogen activator inhibitor-1 in vivoD E Vaughan, P J Declerck, E Van Houtte, et al.
Blood|October 15, 1990
Comparison of intravenous bolus injection or continuous infusion of recombinant single chain urokinase-type plasminogen activator (saruplase) for thrombolysis. A canine model of combined coronary arterial and femoral venous thrombosisH J Rapold, Z M Wu, T Stassen, et al.
The Journal of Clinical Investigation|January 1, 1994
Stimulation with a monoclonal antibody (mAb4E4) of scavenger receptor-mediated uptake of chemically modified low density lipoproteins by THP-1-derived macrophages enhances foam cell generationP Holvoet, G Perez, H Bernar, et al.
Thrombosis and Haemostasis|March 1, 1996
Characterization of a cDNA encoding murine coagulation factor VIIE Idusogie, E Rosen, J P Geng, et al.
Pageof 72